The American Hospital Association is asking the Trump administration to stop Eli Lilly from enacting a new policy that would require all hospitals that participate in a federal drug discount program to submit comprehensive claims data, the first time that a large pharmaceutical company has taken such a step.
The new Lilly policy, which is slated to go into effect on Feb. 1, expands on an earlier move to reduce its costs for selling medicines to hospitals that participate in the 340B Drug Pricing Program. For the past four years, Lilly demanded that only contract pharmacies working with hospitals had to provide claims data.
But as of next week, the company wants all participating hospitals and clinics — except those located in 11 states — to submit claims data in a bid to reduce what it called duplicate discounts, an issue that has riled the pharmaceutical industry and contributed to a long-standing clash with hospitals over the 340B discount program.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply